公开(公告)号：US20240352015A1

公开(公告)日：2024-10-24

申请号：US18755191

申请日：2024-06-26

申请人： Shionogi & Co., Ltd.

发明人： Yoshiyuki TAODA ,  Yuto UNOH

IPC分类号： C07D471/14 ,  A61K31/53 ,  A61P31/18 ,  C07D471/18 ,  C07D487/14 ,  C07D491/22 ,  C07D498/22

CPC分类号： C07D471/14 ,  A61K31/53 ,  A61P31/18 ,  C07D471/18 ,  C07D487/14 ,  C07D491/22 ,  C07D498/22

摘要： The present invention provides a compound represented by Formula (I):




wherein ring A is a substituted or unsubstituted heterocycle; ring C is a benzene ring or the like; R1 is halogen or the like; R2a and R2b are each independently hydrogen or the like; R3 is substituted or unsubstituted alkyl or the like; R4 is hydrogen or the like; and n is an integer of 1 to 3.

公开(公告)号：US12110298B2

公开(公告)日：2024-10-08

申请号：US18369272

申请日：2023-09-18

申请人： AbbVie Inc.

发明人： Mathew M. Mulhern ,  Fredrik Lars Nordstrom ,  Ahmad Y. Sheikh

IPC分类号： C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04

CPC分类号： C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04 ,  C07B2200/13

摘要： The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US12109213B2

公开(公告)日：2024-10-08

申请号：US17858712

申请日：2022-07-06

申请人： Alevere Medical Corporation

发明人： Tim Kamerzell

IPC分类号： A61K31/4985 ,  A61K8/49 ,  A61K9/00 ,  A61K31/496 ,  A61K31/519 ,  A61K31/53 ,  A61Q19/00 ,  A61Q19/06 ,  A61K31/4162 ,  C07D487/14

CPC分类号： A61K31/519 ,  A61K8/4946 ,  A61K8/4953 ,  A61K8/4966 ,  A61K9/0019 ,  A61K31/496 ,  A61K31/4985 ,  A61K31/53 ,  A61Q19/00 ,  A61Q19/06 ,  A61K31/4162 ,  C07D487/14

摘要： The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.

公开(公告)号：US12103933B2

公开(公告)日：2024-10-01

申请号：US18329988

申请日：2023-06-06

申请人： AbbVie Inc.

发明人： Jayanthy Jayanth ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Patrick J. Marroum ,  Peter T. Mayer ,  Ben Klünder

IPC分类号： C07D487/14 ,  A61K9/00 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04

CPC分类号： C07D487/14 ,  A61K9/0053 ,  A61K31/4985 ,  A61K47/02 ,  A61K47/12 ,  A61K47/38 ,  C07D487/04 ,  C07B2200/13

摘要： The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis), kits, methods of synthesis, and products-by-process.

公开(公告)号：US20240287086A1

公开(公告)日：2024-08-29

申请号：US18545487

申请日：2023-12-19

申请人： Incyte Corporation

发明人： Matthew S. McCammant ,  Evan Styduhar ,  Oleg Vechorkin ,  Robert Swyka ,  Wenqing Yao

IPC分类号： C07D487/14 ,  A61P35/00 ,  C07D471/14

CPC分类号： C07D487/14 ,  A61P35/00 ,  C07D471/14

摘要： The present disclosure relates to tricyclic heterocycles, and pharmaceutical compositions of the same, that are inhibitors of the FGFR enzyme and are useful in the treatment of FGFR-associated diseases such as cancer.

公开(公告)号：US20240270746A1

公开(公告)日：2024-08-15

申请号：US18603075

申请日：2024-03-12

申请人： CHIMERIX, INC.

发明人： Joshua E. Allen ,  Martin STOGNIEW ,  Richard S. POTTORF ,  Bhaskara Rao NALLAGANCHU ,  Gary OLSON ,  Yanjun SUN

IPC分类号： C07D471/14 ,  A61K31/337 ,  A61K31/519 ,  A61K45/06 ,  C07D471/12 ,  C07D487/14

CPC分类号： C07D471/14 ,  A61K31/337 ,  A61K31/519 ,  A61K45/06 ,  C07D471/12 ,  C07D487/14 ,  Y02A50/30

摘要： This disclosure relates to methods of treatment using compound (1) or analogs thereof, and pharmaceutically acceptable salts thereof. Also disclosed are compounds of formula (10):




as defined in the specification, and pharmaceutically acceptable salts thereof, as well as pharmaceutical compositions comprising the same. Methods of treatment, such as for cancer, are provided that comprise administering the compounds and their salts to a subject in need of such treatment.

公开(公告)号：US12016862B2

公开(公告)日：2024-06-25

申请号：US17524050

申请日：2021-11-11

申请人： Genentech, Inc.

发明人： Marie Evangelista ,  Mark Andrew Merchant ,  Jennifer Lee Schutzman ,  Ting-Kun Mark Lin ,  Stephanie Royer Joo ,  Sandhya Vinayak Mandlekar ,  Stuart G. Lutzker

IPC分类号： A61P35/00 ,  A61K31/517 ,  C07D487/14 ,  C07K16/22

CPC分类号： A61K31/517 ,  A61P35/00 ,  C07K16/22

摘要： Provided herein are combination therapies comprising a KRasG12C inhibitor (e.g. Compound 1 or a pharmaceutically acceptable salt thereof) and a VEGF antagonist (e.g., bevacizumab) and methods of using such combination therapies.

公开(公告)号：US20240174681A1

公开(公告)日：2024-05-30

申请号：US17907117

申请日：2021-03-26

申请人： BETTA PHARMACEUTICALS CO., LTD

发明人： Jinheng GAO ,  Xiaofeng XU ,  Liang CHEN ,  Zhongxin SUN ,  Yun ZHANG ,  Xiangyong LIU ,  Lieming DING ,  Jiabing WANG

IPC分类号： C07D487/14 ,  A61K31/519 ,  A61P35/00

CPC分类号： C07D487/14 ,  A61K31/519 ,  A61P35/00

摘要： The present invention relates to a crystalline form and/or maleate, phosphate, L-tartrate, and adipate of the compound represented by the structural formula I, and various crystalline forms of various salt forms, and preparation methods and applications thereof.

公开(公告)号：US11981679B2

公开(公告)日：2024-05-14

申请号：US17884493

申请日：2022-08-09

申请人： IMPETIS BIOSCIENCES LTD.

发明人： Sujay Basu ,  Sachin Thorat ,  Yogesh Shejul ,  Anil Panmand ,  Meena Patel ,  Goraksha Khose ,  Rajesh Bonagiri ,  Dinesh Barawkar ,  Bheemashankar Kulkarni ,  Kasim Mookhtiar

IPC分类号： C07D487/14

CPC分类号： C07D487/14

摘要： The present disclosure relates to a series of tricyclic compounds, their tautomers, polymorphs, stereoisomers, prodrugs, solvates, pharmaceutically acceptable salts, pharmaceutical compositions containing them and methods of treating conditions and diseases that are mediated by adenosine receptor (AR) activity. The disclosure also relates to process of preparation of these tricyclic compounds of Formula I. These compounds are useful in the treatment, prevention or suppression of diseases and disorders that may be susceptible to improvement by antagonism of the adenosine receptor. The disclosure also relates to the process of preparation of the tricyclic compounds, and to pharmaceutical compositions containing them.

D-A-B—Z  (I)

Formula I

公开(公告)号：US11976077B2

公开(公告)日：2024-05-07

申请号：US18176651

申请日：2023-03-01

申请人： AbbVie Inc.

发明人： Aileen L. Pangan ,  Henrique D. Teixeira ,  Mohamed-Eslam F. Mohamed ,  Ahmed A. Othman ,  Ben Klünder ,  Jeffrey W. Voss ,  Robert J. Padley ,  Heidi S. Camp

IPC分类号： C07D487/14 ,  A61K9/00 ,  A61K9/20 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38

CPC分类号： C07D487/14 ,  A61K9/0053 ,  A61K9/2013 ,  A61K9/2027 ,  A61K9/2054 ,  A61K31/4985 ,  A61K47/12 ,  A61K47/38 ,  C07B2200/13

摘要： The present disclosure relates to processes for preparing (3S,4R)-3-ethyl-4-(3H-imidazo[1,2-a]pyrrolo[2,3-e]pyrazin-8-yl)-N-(2,2,2-trifluoroethyl)pyrrolidine-1-carboxamide, solid state forms thereof, and corresponding pharmaceutical compositions, methods of treatment (including treatment of rheumatoid arthritis and atopic dermatitis), kits, methods of synthesis, and products-by-process.